ACX-02 clears Alzheimer's proteins in sleep trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- ACX-02 — the Applied Cognition combination of sedative dexmedetomidine and blood-pressure drug midodrine — cleared misfolded amyloid and tau proteins more effectively than placebo/saline in 19 sleep-deprived adults averaging age 60, in a crossover trial led by Paul Dagum of Applied Cognition in Redwood City, California.
- The team estimates that if ACX-02's effect were sustained over several years, it would delay Alzheimer's onset or worsening by about seven years, based on the amyloid levels typically seen in people who go on to develop the condition.
- ACX-02 appears to work by amplifying slow brain waves during the transition from light to deep sleep, increasing fluid flow through glymphatic channels, and causing blood vessels to dilate and constrict more forcefully, according to team member Jeff Iliff of the University of Washington in Seattle.
- No severe side effects were observed, and unlike the approved antibody therapies lecanemab and donanemab, the approach does not activate the brain's immune cells — a process that carries risks of brain bleeding and swelling.
- Shiju Gu of Harvard, who was not involved, called the work "a significant step forward" and said it could eventually benefit healthy people, while Natalie Beschorner of the German Centre for Neurodegenerative Diseases in Bonn called the seven-year estimate "a hypothesis rather than a prediction of clinical benefit," noting the trial measured blood markers, not actual amyloid clumps in the brain.
- The team plans to verify cognitive benefits in studies involving people with early-stage Alzheimer's disease, and Iliff suggested a pill form of dexmedetomidine might also be developed to treat attention lapses following sleep deprivation.
Why it matters: ACX-02 takes a fundamentally different tack from approved antibody drugs like lecanemab and donanemab: it amplifies the brain's own sleep-driven glymphatic clearance rather than targeting plaques via the immune system, sidestepping the brain-bleeding and swelling risks those antibodies carry. But the trial measured only blood markers of amyloid and tau, not brain plaques, and the seven-year delay figure is an extrapolation — not a measured clinical outcome.
Ask SkimNews
